Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | CF33-hNIS |
| Synonyms | |
| Therapy Description |
CF33-hNIS is a chimeric poxvirus engineered to express human sodium iodide symporter (hNIS), which potentially induces tumor cell death and reduces tumor growth (PMID: 31061881). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| CF33-hNIS | CF33-hNIS is a chimeric poxvirus engineered to express human sodium iodide symporter (hNIS), which potentially induces tumor cell death and reduces tumor growth (PMID: 31061881). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05346484 | Phase I | CF33-hNIS + Pembrolizumab CF33-hNIS CF33-hNIS + Fluorouracil + Leucovorin + Oxaliplatin | A Study of CF33-hNIS (VAXINIA), an Oncolytic Virus, as Monotherapy or in Combination With Pembrolizumab in Adults With Metastatic or Advanced Solid Tumors (MAST) | Recruiting | USA | AUS | 0 |